Recce Pharmaceuticals Ltd. (ASX:RCE) is pioneering the development and commercialization of a new class of antibiotics with broad spectrum activity designed to address the urgent global health problem of antibiotic-resistant superbugs. Recce’s antibiotic’s potency does not diminish even with repeated use. The lead patented candidate, RECCE® 327, has been developed for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria — including their superbug forms.